Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Nguyen GH, Olson LC, Magro CM. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome. Ann Diagn Pathol. 2017;28:54-59.

Giulino-Roth L, van Besien HJ, Dalton T, Totonchy JE, Rodina A, Taldone T, et al. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma. Mol Cancer Ther. 2017;16(9):1779-1790.

Pisapia DJ, Magge R, Ramakrishna R. Improved Pathologic Diagnosis-Forecasting the Future in Glioblastoma. Front Neurol. 2017;8:707.

Pizzi M, Inghirami G. Patient-derived tumor xenografts of lymphoproliferative disorders: are they surrogates for the human disease? Curr Opin Hematol. 2017;24(4):384-392.

Rajappa P, Cobb WS, Vartanian E, Huang Y, Daly L, Hoffman C, et al. Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells. Clin Cancer Res. 2017;23(12):3109-3119.

Carniello JV, Pareja F, Santos-Zabala ML, Edelweiss M. Diagnostic dilemmas and pitfalls in ThinPrep cytology of breast fine needle aspiration biopsy:: Report of Six Cases with Histological Correlates. Diagn Cytopathol. 2017;45(7):655-661.

Gratzinger D, de Jong D, Jaffe ES, Chadburn A, Chan JK, Goodlad JR, et al. T- and NK-Cell Lymphomas and Systemic Lymphoproliferative Disorders and the Immunodeficiency Setting: 2015 SH/EAHP Workshop Report-Part 4. Am J Clin Pathol. 2017;147(2):188-203.

Rosenbaum MW, Pozdnyakova O, Geyer JT, Dal Cin P, Hasserjian RP. Ring chromosome in myeloid neoplasms is associated with complex karyotype and disease progression. Hum Pathol. 2017;68:40-46.

Magro CM, Davis TL, Kurtzman DJ. Epidermotropic marginal zone lymphoma: An uncommon cutaneous B-cell lymphoma responsive to rituximab. JAAD Case Rep. 2017;3(6):474-476.

Olsen SN, Wronski A, Castaño Z, Dake B, Malone C, De Raedt T, et al. Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers. Cancer Discov. 2017;7(2):202-217.